Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
UOSD di Dermatologia, Fondazione Policlinico Tor Vergata, Università degli studi di Roma Tor Vergata, Roma, Italy.
Int J STD AIDS. 2024 Jan;35(1):67-70. doi: 10.1177/09564624231199510. Epub 2023 Sep 10.
Biological therapies represent the gold-standard treatment of severe forms of plaque psoriasis. However, people living with HIV are often under-treated for psoriasis because very limited data are available on the use of biologics in this population. We report four cases of patients affected by HIV and moderate-to-severe plaque psoriasis, all treated with risankizumab, a monoclonal antibody that selectively targets interleukin-23. After 16 weeks, all patients experienced complete or almost complete skin clearance without any adverse events. Data on the effectiveness and safety of biological therapies in people living with HIV are limited to case reports or small case series, especially for the most recently approved inhibitors of interleukin-23. Our experienced, although limited, supports the role of risankizumab as a safe and effective therapy for psoriasis amongst patients living with HIV.
生物制剂是重度斑块状银屑病的标准治疗方法。然而，HIV 感染者的银屑病治疗往往不足，因为在这一人群中使用生物制剂的数据非常有限。我们报告了 4 例 HIV 感染者合并中重度斑块状银屑病患者，他们均接受了 risankizumab（一种选择性靶向白细胞介素-23 的单克隆抗体）治疗。16 周后，所有患者的皮肤均完全或几乎完全清除，无任何不良事件发生。HIV 感染者中生物制剂的有效性和安全性数据仅限于病例报告或小病例系列，特别是对于最近批准的白细胞介素-23 抑制剂。我们的经验有限，但支持 risankizumab 作为一种安全有效的治疗 HIV 感染者银屑病的药物。
